Literature DB >> 30472699

Long-Term Follow-Up of a Case with Dyskeratosis Congenita Caused by NHP2-V126M/X154R Mutation: Genotype-Phenotype Association.

Melek Erdem1, Özlem Tüfekçi1, Şebnem Yılmaz1, İnci Alacacıoğlu2, Hale Ören3.   

Abstract

Dyskeratosis congenita (DC) is a rare inherited syndrome characterized by classical mucocutaneous features and the presence of other clinical features including bone marrow failure, pulmonary fibrosis, liver cirrhosis, and a predisposition to cancer. The symptoms develop at various ages and may manifest over time. Gene mutations associated with DC, such as DC1, TERC, TERT, TINF2, NHP2, NOP10, ACD, CTC1, NAF1, PARN, POT1, RTEL1, STN1, and WRAP53, have been identified in about 70% of patients. Since the number of patients with DC is small and the effect of genetic pathogenic variant may affect the phenotype, we wanted to present the clinical features and course of illness in a patient with NHP2 gene mutation (compound heterozygote for the NHP2 mutations c.376G>A/c.460T>A; amino acid substitutions: p.Val126Met and p.X154Arg) that occurred as a compound heterozygous state.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Bone marrow failure; Dyskeratosis congenita; NHP2 mutation

Mesh:

Substances:

Year:  2018        PMID: 30472699     DOI: 10.1159/000494421

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

Review 1.  Genetics of human telomere biology disorders.

Authors:  Patrick Revy; Caroline Kannengiesser; Alison A Bertuch
Journal:  Nat Rev Genet       Date:  2022-09-23       Impact factor: 59.581

2.  CD8+ T-cell senescence and skewed lymphocyte subsets in young Dyskeratosis Congenita patients with PARN and DKC1 mutations.

Authors:  Ting Zeng; Ge Lv; Xuemei Chen; Lu Yang; Lina Zhou; Ying Dou; Xuemei Tang; Jun Yang; Yunfei An; Xiaodong Zhao
Journal:  J Clin Lab Anal       Date:  2020-05-25       Impact factor: 2.352

3.  A Prognostic Model Based on RNA Binding Protein Predicts Clinical Outcomes in Hepatocellular Carcinoma Patients.

Authors:  Zhongsong Man; Yongqiang Chen; Lu Gao; Guowei Xei; Quanfu Li; Qian Lu; Jun Yan
Journal:  Front Oncol       Date:  2021-02-12       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.